Slide 1: Orion Interim Report 1−3/2022
Orion Interim Report 1−3/2022
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Highlights in January−March 2022
Highlights in January−March 2022
Slide 4: Nubeqa spearheads Orion's growth - war and ever more stressed supply chains causing concerns
Nubeqa spearheads Orion’s growth - war and ever more stressed supply chains causing concerns R&D • ARASENS results published at ASCO GU and in New England Journal of Medicine • Orion is planning to refocus R&D in the future on cancer and pain Business • Nubeqa® sales booked by Orion showed strong gr
Slide 5: Key figures 1−3/2022
Key figures 1−3/2022 Net sales Operating profit Operating profit Cash flow per share margin before financial items 271 71 26% 0.13 MEUR (269) MEUR (75) (28%) EUR (0.19) +1% -5% -30% Interim Report 1−3/2022 © Orion Corporation 28 April 2022 5
Slide 6: Development of net sales in 1−3/2022 vs. 1−3/2021
Development of net sales in 1−3/2022 vs. 1−3/2021 12 5 3 -7 -4 269 -7 -1 271 * Nubeqa® product sales & royalty ** Proprietary Products and Specialty Products *** Animal Health, Fermion and Contract Manufacturing **** Without Nubeqa® royalties The figures in the chart are rounded, which is why the to
Slide 7: Development of operating profit in 1−3/2022 vs. 1−3/2021
Development of operating profit in 1−3/2022 vs. 1−3/2021 75 11 -3 6 0 -14 -4 71 * Product & service sales without sales margin and product mix change and exchange rate effect *** Exchange rate effect on gross margin ** Product sales margin and product mix change but without exchange rate effect The
Slide 8: Geographical breakdown and development of net sales
Geographical breakdown and development of net sales 1−3/2022 1−3/2021 1−3/2022 15% 120 28% +5% 8% 100 +2% 99 94 80 74 76 MEUR 60 +4% -1% -21% 13% 40 37 36 38 40 36% 20 26 20 Finland Scandinavia 0 Other Europe North America RoW RoW = Rest of the World Interim Report 1−3/2022 © Orion Corporation 28 Ap
Slide 9: Solid development in Specialty and Proprietary Products – Animal Health decline
Solid development in Specialty and Proprietary Products – Animal Health decline due to timing of deliveries to partners 1−3/2021 1−3/2022 1−3/2022 +5% 140 7% +7% 5% 120 124 130 100 111 40% 103 80 MEUR 60 -31% -5% 48% 40 20 Proprietary Products 19 13 21 20 0 Specialty Products Specialty Proprietary A
Slide 10: TOP 10 products in 1−3/2022
TOP 10 products in 1−3/2022 EUR million vs. 1−3/2021 1. Easyhaler® product portfolio 31 +20% 2. Stalevo®, Comtess®, Comtan® 30 +4% 3. Nubeqa® 20 +142% 4. Simdax® 12 -15% 5. Solomet® 9 +53% 6. dexdor® 7 -38% 7. Divina® series 7 +17% 8. Burana® 6 +15% 9. Dexdomitor®, Domitor®, Domosedan®, Antisedan® 6
Slide 11: Proprietary Products
Proprietary Products GRION Building well-being
Slide 12: Nubeqa the spearhead of growth
Nubeqa® the spearhead of growth Proprietary Products sales split 1−3/2022 35 +20% +4% 9% 30 27% 31 25 29 30 18% +142% 26 20 -15% -38% -31% MEUR 20 15 15 14 10 12 12 11% 5 8 9 7 7% 28% 0 Easyhaler® Parkinson's Nubeqa® Simdax® Dexdor® Others* portfolio franchise Parkinson's Easyhaler® Dexdor® Simdax®
Slide 13: Nubeqa sales booked by Orion showing strong growth
Nubeqa® sales* booked by Orion showing strong growth +142% 25 20 20 15 MEUR MEUR 10 5 8 0 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2020 2021 2022 Q1'21 Q1'22 * Orion’s sales to Bayer for commercial use + royalties from Bayer Interim Report 1−3/2022 © Orion Corporation 28 April 2022 13
Slide 14: Easyhaler continued on a growth path
Easyhaler® continued on a growth path 40 35 20 30 25 16 MEUR 20 MEUR +22% 15 10 5 12 10 0 +17% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2020 2021 2022 Q1'21 Q1'22 Other Budesonide-formoterol Easyhaler® Interim Report 1−3/2022 © Orion Corporation 28 April 2022 14
Slide 15: Sales of Parkinson's franchise
Sales of Parkinson's franchise +4% 40 35 30 29 30 25 MEUR 20 MEUR 15 +4% 10 5 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1'21 Q1'22 2019 2020 2021 2022 Interim Report 1−3/2022 © Orion Corporation 28 April 2022 15
Slide 16: Dexdor and Simdax - declining as expected
Dexdor® and Simdax® - declining as expected Dexdor® Simdax® -15% 20 -38% 20 15 15 12 15 12 MEUR MEUR 10 10 MEUR MEUR 7 5 5 0 0 Q1'21 Q1'22 Q1'21 Q1'22 2019 2020 2021 2022 2019 2020 2021 2022 Interim Report 1−3/2022 © Orion Corporation 28 April 2022 16
Slide 17: Specialty Products
Specialty Products GRION Building well-being
Slide 18: Growth in all main markets
Growth in all main markets Sales split 1−3/2022 80 +4% 70 13% 60 68 65 50 20% MEUR 40 +2% +17% -3% 52% 30 20 26 20 22 19 17 17 10 15% 0 Finland Scandinavia Eastern RoW Finland Europe & Scandinavia Russia Eastern Europe & Russia 1−3/2021 1−3/2022 Rest of the World (RoW) Interim Report 1−3/2022 © Orio
Slide 19: Self care products driving the growth
Self care products driving the growth +2% Sales split 1−3/2022 100 90 95 92 80 27% 70 60 MEUR 50 +14% 40 30 36 31 20 10 0 73% Generic Self Care prescription drugs products Generic drugs Self-care products 1−3/2021 1−3/2022 Interim Report 1−3/2022 © Orion Corporation 28 April 2022 19
Slide 20: In Finland, Orion's reference priced prescription drugs developed clearly better than the market
In Finland, Orion’s reference priced prescription drugs developed clearly better than the market The market for reference priced The sales of Orion's reference prescription drugs in Finland* priced prescription drugs in (1−3/2022) Finland MEUR 109 (114) MEUR 26 (25) Market development Orion’s develo
Slide 21: Orion is strong in home market Finland
Orion is strong in home market Finland Human pharma market in Finland 1−3/2022 Reference Self-care Medicinal and non-medicinal products priced products in hospital and pharmacy channels: EUR 728 million prescription Orion market share in drugs pharmacy 90 Orion market share in 80 80 70 pharmacy 25%
Slide 22: Research and development
Research and development
Slide 23: Key clinical development pipeline
Key clinical development pipeline Project/compound Indication Phase I Phase II Phase III Registration ARASENS / darolutamide 1 Prostate cancer (mHSPC) Phase I Phase II Phase III Registration ARANOTE / darolutamide 1 Prostate cancer (mHSPC) Phase I Phase II Phase III ODM-208 Prostate cancer (CRPC) Ph
Slide 24: Orion and responsibility
Orion and responsibility Building well-being
Slide 25: Orion's Sustainability Agenda and the war in Ukraine
Active work for a Patient safety as better a top priority environment Orion’s Sustainability Agenda and the war in Ukraine Ethics at the Care for well-being core of our professionals business 25
Slide 26: Business targets and outlook
Business targets and outlook
Slide 27: Focus areas in 2022
Focus areas in 2022 Status on 31 TARGET KPIs 2022 March 2022 Increasing the sales of Significant increase in sales of Nubeqa® booked by Orion the current product portfolio Easyhaler® product portfolio sales increase by more than 5% In-licensing of new products Portfolio enhancement through product a
Slide 28: Outlook for 2022
Outlook for 2022 (published on 10 February 2022) Orion estimates that in 2022 net sales will be Net sales at a similar level as in 2021 (in 2021 net sales were EUR 1,041 million). Operating profit is estimated to be Operating at a similar level as in 2021 profit (in 2021 operating profit was EUR 243
Slide 29: Key assumptions impacting the outlook
Key assumptions impacting the outlook Operating Net sales profit + Nubeqa® + Nubeqa® - Simdax® - Simdax® - dexdor® - dexdor® - Cost inflation - Price competition in generics - Sales & marketing expenses Interim Report 1−3/2022 © Orion Corporation 28 April 2022 29
Slide 30: Upcoming events
Upcoming events Half-Year Financial Report 15/7/2022 Interim Report 1-9/2022 20/10/2022
Slide 31: Building well-being
Building well-being GRIoN Building well-being
Slide 32: Appendix
Appendix GRIoN Building well-being
Slide 33: Net sales and operating profit by quarter (MEUR)
Net sales and operating profit by quarter (MEUR) Net sales Operating profit 350 120 300 100 250 80 200 60 150 40 100 50 20 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 Interim Report 1−3/2022 © Orion Corporation 28 April 2022 33
Slide 34: Quarterly net sales by unit (MEUR)
Quarterly net sales by unit (MEUR) Proprietary Products Specialty Products 150 150 100 100 50 50 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 Animal Health Fermion & Contract Manufacturing 30 30 20 20 10 10 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2018 2019 2020 2021 2022 2018 20